Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Aeglea BioTherapeutics (AGLE) Stock Price
Headlines about Aeglea BioTherapeutics (NASDAQ:AGLE) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.4143713694787 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Thursday, August 3rd. ValuEngine downgraded shares of Aeglea BioTherapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th. Finally, TheStreet downgraded shares of Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research note on Friday, May 26th.
Aeglea BioTherapeutics (NASDAQ AGLE) traded up 5.47% during trading on Friday, hitting $3.28. 42,252 shares of the stock were exchanged. The stock has a 50 day moving average price of $3.32 and a 200-day moving average price of $5.13. Aeglea BioTherapeutics has a 12-month low of $2.81 and a 12-month high of $10.34. The firm’s market capitalization is $53.96 million.
TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/26/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-aeglea-biotherapeutics-agle-stock-price.html.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Stock Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related stocks with our FREE daily email newsletter.